Japan’s Nippon Shinyaku will acquire European rights for a Duchenne muscular dystrophy disease therapy developed by Capricor ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Having already scooped up the U.S. rights to Capricor Therapeutics’ late-stage Duchenne muscular dystrophy (DMD) therapy, ...

(RTTNews) - Capricor Therapeutics, Inc. (CAPR), Tuesday announced a deal with Japan-based Nippon Shinyaku Co., Ltd., to commercialize and distribute deramiocel in Europe, which is used for the ...

Capricor Therapeutics Inc (NASDAQ:CAPR) entered into a binding term sheet with Nippon Shinyaku Co., Ltd., a Japanese ...

Capricor will receive an upfront payment of $20 million subject to execution of the definitive agreement, and there are potential additional development and sales-based milestone payments to Capricor ...

Capricor Therapeutics (CAPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

US biotech Capricor Therapeutics has entered into a binding term sheet with Japanese drugmaker Nippon Shinyaku for the ...

Capricor Therapeutics has a 12-month low of $2.68 and a 12-month high of $7.28. The company has a market cap of $163.73 million, a price-to-earnings ratio of -5.89 and a beta of 3.92.

Capricor Therapeutics, Nippon Shinyaku Sign Binding Term Sheet for Commercialization of Duchenne Muscular Dystrophy Treatment in Europe -Capricor to Receive $15 Million Equity Investment at a 20% ...

On Wednesday, Capricor Therapeutics (NASDAQ:CAPR) shares maintained its Buy rating and a $40.00 price target from H.C. Wainwright. The firm's endorsement follows Capricor's announcement on September ...

While the debate now is over how much the Fed will cut at its September meeting, it's increasingly clear that interest rates are headed lower.